Senior researchers from the Silver Santé Study will be presenting the key findings of the project at the prestigious Alzheimer’s Association International Conference (AAIC) in July.

The teams will gather in Amsterdam from 26-30 July to present their analyses of the data collected from the project’s two major clinical trials – Age Well and SCD Well. Each year, the AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease.

Age Well is examining the impact of an 18-month intervention on healthy older adults aged 65+ in the Caen area of France and expert meditators. The volunteers were randomly assigned to one of three groups – meditation practice, foreign language learning, or a control group that had no intervention.

The SCD Well trial is assessing the impact of a short (8 week) course of either meditation or health education on patients from memory clinics in the UK, France, Spain and Germany.

Project Coordinator, Dr Gaël Chételat, who will be among those attending the conference, says: “As the world’s leading Alzheimer’s conference, the AAIC provides an invaluable opportunity for us to share our findings with the international scientific community.

“We look forward to doing so and to hearing from other scientists about their most recent findings in this important field of research.”

The AAIC conference takes place at the RAI Amsterdam, Europaplein 24, 1078 GZ Amsterdam, in the Netherlands.

The Silver Santé Study consortium pictured at the project’s 2019 annual consortium meeting in Berlin.